282 related articles for article (PubMed ID: 32863421)
1. Beyond Cisplatin: Combination Therapy with Arsenic Trioxide.
Miodragović Ð; Swindell EP; Waxali ZS; Bogachkov A; O'Halloran TV
Inorganica Chim Acta; 2019 Oct; 496():. PubMed ID: 32863421
[TBL] [Abstract][Full Text] [Related]
2. Arsenoplatin-1 Is a Dual Pharmacophore Anticancer Agent.
Miodragović Đ; Merlino A; Swindell EP; Bogachkov A; Ahn RW; Abuhadba S; Ferraro G; Marzo T; Mazar AP; Messori L; O'Halloran TV
J Am Chem Soc; 2019 Apr; 141(16):6453-6457. PubMed ID: 30943017
[TBL] [Abstract][Full Text] [Related]
3. On the mechanism of action of arsenoplatins: arsenoplatin-1 binding to a B-DNA dodecamer.
Troisi R; Tito G; Ferraro G; Sica F; Massai L; Geri A; Cirri D; Messori L; Merlino A
Dalton Trans; 2024 Feb; 53(8):3476-3483. PubMed ID: 38270175
[TBL] [Abstract][Full Text] [Related]
4. Iodide Analogs of Arsenoplatins-Potential Drug Candidates for Triple Negative Breast Cancers.
Miodragović Ð; Qiang W; Sattar Waxali Z; Vitnik Ž; Vitnik V; Yang Y; Farrell A; Martin M; Ren J; O'Halloran TV
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500854
[TBL] [Abstract][Full Text] [Related]
5. The role of arsenic in the hydrolysis and DNA metalation processes in an arsenous acid-platinum(ii) anticancer complex.
Marino T; Parise A; Russo N
Phys Chem Chem Phys; 2017 Jan; 19(2):1328-1334. PubMed ID: 27966695
[TBL] [Abstract][Full Text] [Related]
6. Platinum(II) complexes of imidazophenanthroline-based polypyridine ligands as potential anticancer agents: synthesis, characterization, in vitro cytotoxicity studies and a comparative ab initio, and DFT studies with cisplatin, carboplatin, and oxaliplatin.
Alexander C; Nithyakumar A; Paul MWB; Arockia Samy N
J Biol Inorg Chem; 2018 Jul; 23(5):833-848. PubMed ID: 29934700
[TBL] [Abstract][Full Text] [Related]
7. The first step of arsenoplatin-1 aggregation in solution unveiled by solving the crystal structure of its protein adduct.
Ferraro G; Cirri D; Marzo T; Pratesi A; Messori L; Merlino A
Dalton Trans; 2021 Jan; 50(1):68-71. PubMed ID: 33320144
[TBL] [Abstract][Full Text] [Related]
8. Lipid encapsulation of arsenic trioxide attenuates cytotoxicity and allows for controlled anticancer drug release.
Chen H; MacDonald RC; Li S; Krett NL; Rosen ST; O'Halloran TV
J Am Chem Soc; 2006 Oct; 128(41):13348-9. PubMed ID: 17031934
[TBL] [Abstract][Full Text] [Related]
9. Evaluation for Synergistic Effects by Combinations of Photodynamic Therapy (PDT) with Temoporfin (mTHPC) and Pt(II) Complexes Carboplatin, Cisplatin or Oxaliplatin in a Set of Five Human Cancer Cell Lines.
Lange C; Bednarski PJ
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30332729
[TBL] [Abstract][Full Text] [Related]
10. Advancements in the Use of Platinum Complexes as Anticancer Agents.
Sharma R; Singh VJ; Chawla PA
Anticancer Agents Med Chem; 2022; 22(5):821-835. PubMed ID: 34353272
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide and tetraarsenic oxide induce cytotoxicity and have a synergistic effect with cisplatin in paclitaxel-resistant ovarian cancer cells.
Byun JM; Lee DS; Landen CN; Kim DH; Kim YN; Lee KB; Sung MS; Park SG; Jeong DH
Acta Oncol; 2019 Nov; 58(11):1594-1602. PubMed ID: 31257975
[No Abstract] [Full Text] [Related]
12. Facile synthesis of aquo-cisplatin arsenite multidrug nanocomposites for overcoming drug resistance and efficient combination therapy.
Xin J; Zhang K; Huang J; Luo X; Gong X; Yang Z; Lin H; Shan H; Gao J
Biomater Sci; 2018 Dec; 7(1):262-271. PubMed ID: 30465673
[TBL] [Abstract][Full Text] [Related]
13. Anticancer activity of small-molecule and nanoparticulate arsenic(III) complexes.
Swindell EP; Hankins PL; Chen H; Miodragović DU; O'Halloran TV
Inorg Chem; 2013 Nov; 52(21):12292-304. PubMed ID: 24147771
[TBL] [Abstract][Full Text] [Related]
14. A prospective trial to evaluate the clinical efficacy and safety of neoadjuvant chemotherapy with arsenic trioxide and carboplatin in locally advanced cervical cancer: a study protocol for randomized controlled clinical.
He ZY; Li HY; Yan J; Li SJ; Li DC; Liang ZZ
Trials; 2022 Jul; 23(1):556. PubMed ID: 35804452
[TBL] [Abstract][Full Text] [Related]
15. Improved apoptotic cell death in drug-resistant non-small-cell lung cancer cells by tumor necrosis factor-related apoptosis-inducing ligand-based treatment.
Gatti L; Cossa G; Tinelli S; Carenini N; Arrighetti N; Pennati M; Cominetti D; De Cesare M; Zunino F; Zaffaroni N; Perego P
J Pharmacol Exp Ther; 2014 Mar; 348(3):360-71. PubMed ID: 24345465
[TBL] [Abstract][Full Text] [Related]
16. Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors.
Sönksen M; Kerl K; Bunzen H
Med Res Rev; 2022 Jan; 42(1):374-398. PubMed ID: 34309879
[TBL] [Abstract][Full Text] [Related]
17. Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants.
Tummala R; Diegelman P; Hector S; Kramer DL; Clark K; Zagst P; Fetterly G; Porter CW; Pendyala L
Cancer Chemother Pharmacol; 2011 Feb; 67(2):401-14. PubMed ID: 20443003
[TBL] [Abstract][Full Text] [Related]
18. Urinary excretion of platinum, arsenic and selenium of cancer patients from the Antofagasta region in Chile treated with platinum-based drugs.
Román DA; Pizarro I; Rivera L; Torres C; Avila J; Cortés P; Gill M
BMC Res Notes; 2012 Apr; 5():207. PubMed ID: 22546077
[TBL] [Abstract][Full Text] [Related]
19. Interaction of oxaliplatin, cisplatin, and carboplatin with hemoglobin and the resulting release of a heme group.
Mandal R; Kalke R; Li XF
Chem Res Toxicol; 2004 Oct; 17(10):1391-7. PubMed ID: 15487901
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
